Page 295 - Read Online

Bracht et al. J Cancer Metastasis Treat 2019;5:22 I http://dx.doi.org/10.20517/2394-4722.2018.111 Page 9 of 10

Performed data acquisition, as well as provided administrative, technical, and material support: Bracht
JWP, Karachaliou N, Berenguer J, Fernandez-Bruno M, Filipska M, Pedraz-Valdunciel C, Codony-Servat C,
Codony-Servat J, Rosell R

Availability of data and materials
Not applicable.

Financial support and sponsorship
Work in Dr. Rosell’s laboratory is partially supported by a grant from La Caixa Foundation; an Instituto
de Salud Carlos III grant (RESPONSE, PIE16/00011, PI14/01678); a Marie Skłodowska-Curie Innovative
Training Networks European Grant (ELBA No 765492); and a Spanish Association Against Cancer (AECC)
grant (PROYE18012ROSE).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
Science 2004;305:1163-7.
2. Lazzara MJ, Lane K, Chan R, Jasper PJ, Yaffe MB, et al. Impaired SHP2-mediated extracellular signal-regulated kinase activation
contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Cancer Res
2010;70:3843-50.
3. Karachaliou N, Fernandez-Bruno M, Bracht JWP, Rosell R. EGFR first- and second-generation TKIs-there is still place for them in EGFR-
mutant NSCLC patients. Transl Cancer Res 2018; doi: 10.21037/tcr.2018.10.06.
4. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, et al. Erlotinib versus standard chemotherapy as first-line treatment for
European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised
phase 3 trial. Lancet Oncol 2012;13:239-46.
5. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, et al. Osimertinib in untreated EGFR-mutated advanced non-
small-cell lung cancer. N Engl J Med 2018;378:113-25.
6. Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, et al. Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in
EGFR-mutant NSCLC. J Natl Cancer Inst 2017;109.
7. Codony-Servat C, Codony-Servat J, Karachaliou N, Molina MA, Chaib I, et al. Activation of signal transducer and activator of transcription
3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). Oncotarget 2017;8:47305-16.
8. Karachaliou N, Chaib I, Cardona AF, Berenguer J, Bracht JWP, et al. Common Co-activation of AXL and CDCP1 in EGFR-mutation-
positive Non-smallcell lung cancer associated with poor prognosis. EBioMedicine 2018;29:112-27.
9. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in
human lung adenocarcinomas. J Clin Invest 2007;117:3846-56.
10. Fan W, Tang Z, Yin L, Morrison B, Hafez-Khayyata S, et al. MET-independent lung cancer cells evading EGFR kinase inhibitors are
therapeutically susceptible to BH3 mimetic agents. Cancer Res 2011;71:4494-505.
11. Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer
Cell 2014;26:207-21.
12. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor
and interleukin-6. Science 1994;264:95-8.
13. Nan J, Du Y, Chen X, Bai Q, Wang Y, et al. TPCA-1 is a direct dual inhibitor of STAT3 and NF-kappaB and regresses mutant EGFR-
associated human non-small cell lung cancers. Mol Cancer Ther 2014;13:617-29.
14. Tursynbay Y, Zhang J, Li Z, Tokay T, Zhumadilov Z, et al. Pim-1 kinase as cancer drug target: An update. Biomed Rep 2016;4:140-6.